MCE® MedChemExpress

Product Data Sheet

Felvizumab

Cat. No.:	HY-P99615
CAS No.:	167747-20-8
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2].
IC$_{50}$ & Target	EC50: 0.49 μg/mL (RSV Type A in microneutralization assay), 0.95 μg/mL (RSV Type A in fusion inhibition assay)[2]
In Vitro	Felvizumab (RSHZ19) (2 h or 4 h) inhibits RSV Type A with an EC$_{50}$ of 0.49 ± 0.37 μg/mL in microneutralization assay and with an EC$_{50}$ of 0.95 ± 0.13 μg/mL in fusion inhibition assay[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) is effective against A and B subtypes of RSV in the cotton rat model of RSV infection[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cotton rats, RSV infection model[2]
Dosage:	0.625, 1.25, 2.5, and 5.0 mg/kg
Administration:	Intramuscular injection, 1 day before infection
Result:	Significantly reduced lung RSV titer.

REFERENCES

[1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-97.

[2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999 Jul;180(1):35-40.

Caution: Product has not been fully validated for medical applications. For research use only.